Shuichiro Uehara

Prof. Dr. Shuichiro Uehara

orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
SHShun Horaguchi
Shun Horaguchi
YNYoshiro Nakahara
Yoshiro Nakahara
YIYuka Igarashi
Yuka Igarashi
TKTaku Kouro
Taku Kouro
FWFeifei WEI
Feifei WEI
Tetsuro SasadaTetsuro Sasada
Tetsuro Sasada
Neutrophil extracellular traps (NETs) released from neutrophils are related to cancer progression. However, the relationship between the therapeutic effects of immune checkpoint inhibitors (ICIs) such as anti-PD-1 and anti-PD-L1 antibodies and plasma NET concentration in patients with non-small cell lung cancer (NSCLC) is poorly understood. In this study, concentrations of citrullinated histone H3 (CitH3), a surrogate marker of NETs, in plasma before/after treatment were examined in patients with advanced or recurrent NSCLC undergoing ICI treatment (n = 185). The clinical significances of NET levels before/after treatment and posttreatment changes were statistically evaluated. As a result, multivariate Cox analysis showed that high NET levels before treatment were statistically significant predictors of unfavorable overall survival (OS; p < 0.001, HR 1.702, 95% CI 1.356–2.137) and progression-free survival (PFS; p < 0.001, HR 1.566, 95% CI 1.323–1.855). The Kaplan-Meier curves showed significant separation between the high- and low-NET groups in OS (p = 0.002) and PFS (p < 0.001). Additionally, high NET levels after treatment were also significantly associated with worse OS (p < 0.001) and PFS (p < 0.001) by multivariate Cox analysis. Notably, the pretreatment NET levels were significantly correlated with the plasma levels of NET-related inflammatory cytokines, such as IL-6 and IL-8, and with NET-related gene expression and immune-suppressive profile in peripheral blood mononuclear cells. Our findings suggest that NETs released from activated neutrophils might reduce the clinical efficacy of ICIs in patients with NSCLC.

31 December 2011 in Journal of Pediatric Surgery
Verified
Journal Article
Closed access
TOTakaharu Oue
Takaharu Oue
SUShuichiro Uehara
Shuichiro Uehara
HYHiroaki Yamanaka
Hiroaki Yamanaka
YTYuichi Takama
Yuichi Takama
YOYusuke Oji
Yusuke Oji
MFMasahiro Fukuzawa
Masahiro Fukuzawa

26 February 2013 in European Journal of Pediatric Surgery
Verified
Journal Article
Closed access
TOTakaharu Oue
Takaharu Oue
MKMiyoko Kawatsu
Miyoko Kawatsu
KNKeigo Nara
Keigo Nara
MFMasahiro Fukuzawa
Masahiro Fukuzawa
SUShuichiro Uehara
Shuichiro Uehara
Background Survivin, an inhibitor of apoptosis, has been reported to be associated with a worse prognosis in some malignancies. However, its expression in hepatoblastoma (HB) remains to be elucidated. We assessed the survivin expression in HB specimens collected before and after chemotherapy to elucidate the impact of survivin on the outcome of HB therapy. Methods HB specimens were collected before and after 2 to 4 cycles of cisplatin-based chemotherapy from 16 patients. The survivin expression level was assessed by immunohistochemical staining and real-time polymerase chain reaction. Results Out of 16, 12 HB sections collected before chemotherapy were positive for survivin as determined by immunohistochemical staining. The intensity of survivin expression was found to significantly increase after chemotherapy. Surprisingly, all of the HB specimens obtained after chemotherapy were positive for survivin. The expression of survivin messenger ribonucleic acid from a human HB cell line, Huh-6 was significantly higher when the cells were cultured with cis-diamminedichloroplatinum(II) than when the cells were cultured without the drug. Conclusion Our results indicate that most of the primary HB tissue specimens express survivin, and its expression increased after chemotherapy, thus suggesting that survivin may concern with the survival of tumor cells, therefore be a candidate for the target of the treatment of HB.

16 March 2015 in European Journal of Pediatric Surgery
Verified
Journal Article
Closed access
PDF file
NUNoriaki Usui
Noriaki Usui
TKTakeshi Kanagawa
Takeshi Kanagawa
TYTaku Yamamichi
Taku Yamamichi
KNKeigo Nara
Keigo Nara
TUTakehisa Ueno
Takehisa Ueno
SUSatoshi Umeda
Satoshi Umeda
Purpose The aim of this study was to clarify the prenatal and postnatal clinical courses of an urachus identified as an allantoic cyst in the umbilical cord. Methods Allantoic cysts in the umbilical cord were identified in five fetuses over the past 12 years at our hospital. The prenatal and postnatal clinical courses of these patients were retrospectively reviewed. Results The presence of allantoic cysts in the umbilical cord was first detected at 15 to 27 weeks of gestation. The cysts subsequently became enlarged, reaching a maximum diameter of 34 to 61 mm at 17 to 32 weeks of gestation. The cysts then suddenly disappeared due to spontaneous rupture at 26 to 35 weeks of gestation. After being born at 38 (35–39) weeks of gestation, four patients were diagnosed with a patent urachus requiring surgery in the infantile period and one was diagnosed with an urachal cyst, which is currently being observed without surgery. Conclusion The presence of an urachus identified as an allantoic cyst in the umbilical cord is frequently associated with spontaneous rupture during the prenatal period, resulting in a patent urachus after birth that requires surgical intervention.

23 June 2017 in Pediatrics International
Verified
Journal Article
Closed access
PDF file
SUShuichiro Uehara
Shuichiro Uehara
AYAkihiro Yoneda
Akihiro Yoneda
TOTakaharu Oue
Takaharu Oue
KNKengo Nakahata
Kengo Nakahata
MZMasahiro Zenitani
Masahiro Zenitani
HOHiroomi Okuyama
Hiroomi Okuyama

7 September 2021 in Pediatric Surgery International
Verified
Journal Article
Closed access
PDF file
BYBin Yamaoka
Bin Yamaoka
ENEri Nagasaki-Maeoka
Eri Nagasaki-Maeoka
SUShota Uekusa
Shota Uekusa
AHAyano Hidaka
Ayano Hidaka
KHKohei Hijikata
Kohei Hijikata
SUShuichiro Uehara
Shuichiro Uehara